New therapy could help manage atopic dermatitis
A novel treatment could be effective in treating atopic dermatitis.
In a Phase 2 randomized clinical trial published in JAMA Dermatology, researchers analyzed the safety and efficacy of the tyrosine kinase 2 inhibitor ICP-332 compared with placebo in 75 patients aged 18 to 75 years with moderate to severe atopic dermatitis. The patients were randomly assigned to receive either 80 or 120 milligrams of ICP-332 or placebo for a period of four weeks.
The researchers found that the patients who received ICP-332 had greater reductions in their Eczema Area and Severity Index scores by Week 4 compared with those who received placebo. Further, the researchers observed mostly mild treatment-related adverse effects and no severe adverse effects or mortality.
The positive results supported the further assessment of ICP-332 in the treatment of moderate to severe atopic dermatitis.
Read more: JAMA Dermatology
The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.